Adage Capital Partners Gp, L.L.C. Xenon Pharmaceuticals Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$52.3 Billion
Q2 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,839,555 shares of XENE stock, worth $71.1 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

1,839,555

Previous 1,671,917 10.03%

Holding current value

$71.1 Million

Previous $72 Million 0.35%

% of portfolio

0.14%

Previous 0.14%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$36.25 - $43.75 $6.08 Million - $7.33 Million	167,638 Added 10.03%	1,839,555 $71.7 Million
Q1 2024 May 15, 2024	BUY	$42.66 - $50.04 $26.6 Million - $31.2 Million	623,192 Added 59.42%	1,671,917 $72 Million
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $14.3 Million - $23.2 Million	498,725 Added 90.68%	1,048,725 $48.3 Million
Q3 2023 Nov 14, 2023	SELL	$34.16 - $39.73 $4.1 Million - $4.77 Million	-120,000 Reduced 17.91%	550,000 $18.8 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $2.79 Million - $3.48 Million	-80,000 Reduced 10.67%	670,000 $25.8 Million
Q1 2023 May 15, 2023	BUY	$33.46 - $40.35 $836,500 - $1.01 Million	25,000 Added 3.45%	750,000 $26.8 Million
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $1.65 Million - $1.97 Million	50,000 Added 7.41%	725,000 $28.6 Million
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $1.39 Million - $1.79 Million	45,000 Added 7.14%	675,000 $24.4 Million
Q2 2022 Aug 15, 2022	SELL	$25.44 - $35.16 $508,800 - $703,199	-20,000 Reduced 3.08%	630,000 $19.2 Million
Q1 2022 May 16, 2022	SELL	$25.09 - $33.13 $376,350 - $496,950	-15,000 Reduced 2.26%	650,000 $19.9 Million
Q4 2021 Feb 14, 2022	SELL	$15.6 - $35.4 $7.96 Million - $18.1 Million	-510,000 Reduced 43.4%	665,000 $20.8 Million
Q3 2021 Nov 15, 2021	SELL	$14.86 - $19.45 $5.2 Million - $6.81 Million	-350,000 Reduced 22.95%	1,175,000 $18 Million
Q2 2021 Aug 16, 2021	SELL	$16.81 - $20.0 $17.2 Million - $20.5 Million	-1,025,000 Reduced 40.2%	1,525,000 $28.4 Million
Q1 2021 May 17, 2021	BUY	$13.65 - $21.31 $1.37 Million - $2.13 Million	100,000 Added 4.08%	2,550,000 $45.6 Million
Q3 2020 Nov 16, 2020	BUY	$10.82 - $13.35 $4.6 Million - $5.67 Million	425,000 Added 20.99%	2,450,000 $27.1 Million
Q1 2020 May 15, 2020	BUY	$8.08 - $17.57 $808,000 - $1.76 Million	100,000 Added 5.19%	2,025,000 $23 Million
Q4 2019 Feb 14, 2020	BUY	$8.11 - $14.65 $5.07 Million - $9.16 Million	625,000 Added 48.08%	1,925,000 $25.2 Million
Q4 2018 Feb 14, 2019	BUY	$5.61 - $12.62 $561,000 - $1.26 Million	100,000 Added 8.33%	1,300,000 $8.2 Million
Q3 2018 Nov 14, 2018	BUY	$9.0 - $14.9 $3.6 Million - $5.96 Million	400,000 Added 50.0%	1,200,000 $15.8 Million
Q2 2018 Aug 14, 2018	BUY	$4.8 - $9.2 $3.84 Million - $7.36 Million	800,000 New	800,000 $7.36 Million

Others Institutions Holding XENE

# of Institutions

221

Shares Held

69.6M

Call Options Held

59.7K

Put Options Held

60.7K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.41B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Xenon Pharmaceuticals Inc. Transaction History